Genmab — December 2018
-
-
MedicalResearch.com Interview with:
Peter Voorhees, MD - CENTAURUS - https://medicalresearch.com/cancer-_-oncology/ash18-centaurus-study-evaluates-dosing-schedule-of-darzalex/46313/
-
-
Despite interesting durable responses & low rates of infusion-related reactions $MOR s Anti-CD38 MOR202 will NOT be further developed in EU and US https://twitter.com/ThiloZander/status/1068972296281350144
-
MAIA præsenteres tirsdag 16:30 https://twitter.com/atriumhealth/status/1069045327863283714?s=21
-
80% MRD- dara + KRd https://twitter.com/drolalandgren/status/1069250815368392704?s=21
-
Den tør man ikke tænke på....
-
Er der overraskelser - positive/negative?
-
KCRD does not look bad https://twitter.com/theMMRF/status/1069260099263188994
-
dara plus IRd impressive https://twitter.com/ninashah33/status/1069267606647885824?s=21
-
Ser man på omkostninger og effektivitet kan dara+CyBorD blive vigtigt. Lyra. https://www.youtube.com/watch?v=z6vkzZYUJfM
-
CyBorD plus dara MRD- ca. 80% https://twitter.com/michaelodwyermd/status/1069278701676720128?s=21
-
Det må vel betegnes som overordentlig positivt:-)
-
in Syros press release
SY-1425 Induced CD38 Expression in Majority of Patients in Daratumumab Combination Cohort in Relapsed/Refractory AML and Higher-Risk MDS Patientshttps://www.businesswire.com/news/home/20181202005039/en/Syros-Announces-Promising-Clinical-Data-Ongoing-Phase 2 -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind